Geron Corporation to Present at BIO CEO Conference
Friday February 10, 7:30 am ET
MENLO PARK, Calif.--(BUSINESS WIRE)--Feb. 10, 2006--Geron Corporation (Nasdaq:GERN - News) will be presenting an update of the company's product development programs on Tuesday, February 14, 2006, at the Biotechnology Industry Organization's CEO and Investor Conference at 10:30 a.m., Eastern Time in New York City.
The update of Geron's portfolio of telomerase-based anti-cancer therapies will include the inhibitor drug, GRN163L, and the therapeutic vaccine, GRNVAC1. The presentation will also include reviews of the company's human embryonic stem cell (hESC) development programs for spinal cord injury (GRNOPC1), diabetes (GRNIPC1) and heart disease (GRNCM1). Thomas B. Okarma, Ph.D., M.D., Geron's president and chief executive officer, will be giving the presentation.
The audio and slide presentation will be available at the following website address: corporate-ir.net confLobby.zhtml?ticker=GERN&item_id=1165933. (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.) A replay will be available at this address within 24 hours of the presentation and for a period of 30 days.
In addition, Dr. Okarma will participate in a Focus Session entitled Cell Therapy: Getting Around the Embryonic Stem Cell Issue on Wednesday, February 15, 2006 at 3:30 p.m. Eastern Time. The audio for this panel discussion will be available approximately 12 hours after the session at the following website address: ceo.bio.org. A replay will be available for a period of 30 days.
For further information, please contact Geron Corporation at 650-473-7765 or visit Geron's website at www.geron.com.
Geron is a biopharmaceutical company focused on developing and commercializing three groups of products: i) therapeutic products for oncology that target telomerase; ii) pharmaceuticals that activate telomerase in tissues impacted by senescence, injury or degenerative disease; and iii) cell-based therapies derived from its human embryonic stem cell platform for applications in multiple chronic diseases. |
